Previous 10 | Next 10 |
2023-12-12 11:25:00 ET Summary Retail inflation rose slightly in November, giving the Fed some leeway to jawbone yields higher. Core inflation remained in line with expectations despite a surge in used car prices, which economists expect to decline in the coming months. Oracle...
2023-12-12 09:59:18 ET DENVER, Colo., Dec. 12, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Aditxt Inc (NASDAQ: ADTX), C4 Therapeutics Inc. (NASDAQ: CCCC), IN8bio Inc. (NASDAQ: INAB), Candel Therapeuti...
2023-12-12 09:42:28 ET A Massachusetts-based %Biotech company is stealing the show so far during Tuesday’s premarket hours after it was announced that it has entered into an exclusive license and collaboration agreement with Merck (known as MSD outside of the U.S. and Canada) to ...
2023-12-12 09:06:38 ET DENVER, Colo., Dec. 12, 2023 ( www.247marketnews.com )- The following companies are our five favorite trades of the day; Siyata Mobile Inc. (NASDAQ: SYTA), Aditxt Inc (NASDAQ: ADTX), C4 Therapeutics Inc. (NASDAQ: CCCC), IN8bio Inc. (NASDAQ: INAB), Alphabet Inc (NA...
2023-12-12 07:41:19 ET DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- C4 Therapeutics, Inc. (NASDAQ: CCCC) stated, this morning, that it entered into an exclusive license and collaboration agreement with Merck to develop degrader-antibody conjugates (DACs), an emerging modality ...
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, toda...
2023-11-06 13:42:49 ET More on C4 Therapeutics C4 Therapeutics: Way Too Long A Wait For This One Seeking Alpha’s Quant Rating on C4 Therapeutics Historical earnings data for C4 Therapeutics Financial information for C4 Therapeutics For further ...
C4 Therapeutics Inc. (CCCC) is expected to report $-0.65 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...